Miracle Pharmaceutical released its first quarter report for 2024 on the evening of April 29, and again on the evening of April 30.
A reporter from the China Securities Journal found that the reason for the release of the two quarterly reports may be that the title of the announcement released by Miracle Pharmaceutical on the evening of April 29 was incorrect, and it was written as "2023 Annual Report and First Quarter Report of 2024".
After discovering this error, the company quickly corrected it and reissued it.
Image source: Juchao Information Network
Compared with the two first-quarter reports, in addition to the different titles of the announcement, there is also a change in the time of the announcement, which changed the previous April 28, 2024 to April 30, 2024.
Since November 27, 2023, the share price of Miracle Pharmaceutical has fluctuated, and as of the close of trading on May 6, the stock price has fallen by more than 20%.
According to the latest 2024 first quarter report released by Miracle Pharmaceutical, the company achieved operating income of 575 million yuan in the first quarter, a year-on-year decrease of 1.42%, and net profit attributable to the parent company was 23.9447 million yuan, a year-on-year increase of 0.65%.
The main business of Miracle Pharmaceutical includes two sectors: pharmaceutical manufacturing and pharmaceutical commerce. Among them, in the pharmaceutical manufacturing industry, the company's main business is the research and development, production and sales of drugs, and the products involve anti-tumor, cold and cough, cardiovascular and cerebrovascular, rheumatism and bone pain, antifungal, tonic and soothing nerves, gynecology and other therapeutic fields. According to the 2023 annual report, the company's pharmaceutical manufacturing revenue accounted for 61.13% of operating income during the reporting period.
In terms of pharmaceutical business, the company mainly takes the holding companies Shandong Magic and Chongqing Miracle Kangzheng as the pharmaceutical business platform, which is engaged in the distribution, wholesale and retail of pharmaceutical products, and sells the pharmaceutical products of the company and other enterprises. According to the 2023 annual report, the company's pharmaceutical business revenue accounted for 38.87% of operating income during the reporting period.
Reviewer: Ren Mingjie Editor: Yu Hongbo Proofreader: Wang Yin Producer: Li Ruoyu Signed: Sun Hong